Paper20194151
Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.
Madan S and 8 others. Mayo Clin Proc, 2010. Cited by 77 papers, by iCite.
Cite this record
ConductScience Library. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Papers, record 20194151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20194151
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amyloidosis | Major topic |
| Antineoplastic Agents | Major topic |
| Immunoglobulin Light Chains | Major topic |
| Multiple Myeloma | Major topic |
| Peripheral Blood Stem Cell Transplantation | Major topic |
| Aged | |
| Aged, 80 and over | |
| Biopsy | |
| Diagnosis, Differential | |
| Dose-Response Relationship, Drug | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Middle Aged | |
| Prospective Studies | |
| Survival Rate | |
| Treatment Outcome | |
| United States |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P01 CA062242 | NCI NIH HHS | United States | P01CA062242 | PubMed and NIH |
| CA 62242 | NCI NIH HHS | United States | P01CA062242 | PubMed and NIH |
Source NIH RePORTER
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1582977 | Diagnostic criteria of multiple myeloma. | Hematol Oncol Clin North Am | 1992 | https://conductscience.org/library/papers/1582977 | PubMed |
| 2 | 16198646 | Clinical aspects of systemic amyloid diseases. | Biochim Biophys Acta | 2005 | https://conductscience.org/library/papers/16198646 | PubMed |
| 3 | 18648809 | Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. | Ann Hematol | 2009 | https://conductscience.org/library/papers/18648809 | PubMed |
| 4 | 16715110 | Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? | Bone Marrow Transplant | 2006 | https://conductscience.org/library/papers/16715110 | PubMed |
| 5 | 12780789 | Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. | Br J Haematol | 2003 | https://conductscience.org/library/papers/12780789 | PubMed |
| 6 | 7878478 | Primary systemic amyloidosis: clinical and laboratory features in 474 cases. | Semin Hematol | 1995 | https://conductscience.org/library/papers/7878478 | PubMed |
| 7 | 9674753 | Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. | Br J Haematol | 1998 | https://conductscience.org/library/papers/9674753 | PubMed |
| 8 | 9573002 | Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. | Blood | 1998 | https://conductscience.org/library/papers/9573002 | PubMed |
| 9 | 11856795 | A long-term study of prognosis in monoclonal gammopathy of undetermined significance. | N Engl J Med | 2002 | https://conductscience.org/library/papers/11856795 | PubMed |
| 10 | 12036853 | Autologous stem cell transplantation for primary systemic amyloidosis. | Blood | 2002 | https://conductscience.org/library/papers/12036853 | PubMed |
| 11 | 9402328 | Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. | Leuk Lymphoma | 1997 | https://conductscience.org/library/papers/9402328 | PubMed |
| 12 | 16011989 | Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis. | Amyloid | 2005 | https://conductscience.org/library/papers/16011989 | PubMed |
| 13 | 9554527 | Primary systemic amyloidosis with delayed progression to multiple myeloma. | Cancer | 1998 | https://conductscience.org/library/papers/9554527 | PubMed |
| 14 | 16571879 | Prevalence of monoclonal gammopathy of undetermined significance. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16571879 | PubMed |
| 15 | 18162215 | Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). | Biol Blood Marrow Transplant | 2008 | https://conductscience.org/library/papers/18162215 | PubMed |
| 16 | 12515719 | Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). | Blood | 2003 | https://conductscience.org/library/papers/12515719 | PubMed |
| 17 | 15070667 | Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. | Blood | 2004 | https://conductscience.org/library/papers/15070667 | PubMed |
| 18 | 15180858 | Guidelines on the diagnosis and management of AL amyloidosis. | Br J Haematol | 2004 | https://conductscience.org/library/papers/15180858 | PubMed |
| 19 | 16044444 | Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. | Am J Hematol | 2005 | https://conductscience.org/library/papers/16044444 | PubMed |
| 20 | 9578896 | The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. | QJM | 1998 | https://conductscience.org/library/papers/9578896 | PubMed |
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42488491 | Cardiac amyloidosis risk across ethnoracial and clinical subgroups: a five-year national study. | Am J Cardiovasc Dis | 2026 | https://conductscience.org/library/papers/42488491 | PubMed |
| 42454121 | The value of speckle tracking echocardiography in early identification of subclinical cardiac involvement in patients with multiple myeloma: a pilot retrospective study. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42454121 | PubMed |
| 42305798 | Real-World Diagnostic Workup of Patients Suspected for Light Chain Amyloidosis and Wild-Type Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using US Electronic Health Records. | EJHaem | 2026 | https://conductscience.org/library/papers/42305798 | PubMed |
| 41994108 | Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure. | Res Sq | 2026 | https://conductscience.org/library/papers/41994108 | PubMed |
| 41664246 | The impact of cardiac amyloidosis on patients with multiple myeloma: a systematic review and meta-analysis. | Cardiooncology | 2026 | https://conductscience.org/library/papers/41664246 | PubMed |
| 41291170 | Amyloid Light Chain Proteins in Cardiovascular Disease: Pathogenesis and Emerging Therapies for Cardiac Amyloidosis. | Pharm Res | 2025 | https://conductscience.org/library/papers/41291170 | PubMed |
| 41233352 | Oligomeric cystatin C supports the immunosuppressive activity of myeloid cells through interaction with inhibitory receptors. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/41233352 | PubMed |
| 40650957 | Recent developments in systemic light-chain amyloidosis prognosis and treatment. | Future Cardiol | 2025 | https://conductscience.org/library/papers/40650957 | PubMed |
| 40631729 | Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. | Eur Heart J | 2025 | https://conductscience.org/library/papers/40631729 | PubMed |
| 40475717 | Prevalence of Atrial Fibrillation and Intervention Therapy in Cardiac Amyloidosis. | Rev Cardiovasc Med | 2025 | https://conductscience.org/library/papers/40475717 | PubMed |
| 39598451 | Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39598451 | PubMed |
| 39587494 | Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes. | BMC Cancer | 2024 | https://conductscience.org/library/papers/39587494 | PubMed |
| 39540049 | A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/39540049 | PubMed |
| 39476401 | Mexican position paper for the diagnosis and treatment of cardiac amyloidosis. | Arch Cardiol Mex | 2024 | https://conductscience.org/library/papers/39476401 | PubMed |
| 38283805 | An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities. | Saudi J Biol Sci | 2024 | https://conductscience.org/library/papers/38283805 | PubMed |
| 37909849 | B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma. | ESC Heart Fail | 2024 | https://conductscience.org/library/papers/37909849 | PubMed |
| 37511893 | AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor. | Life (Basel) | 2023 | https://conductscience.org/library/papers/37511893 | PubMed |
| 37381778 | Amyloidogenic light chains impair plasma cell survival. | Haematologica | 2023 | https://conductscience.org/library/papers/37381778 | PubMed |
| 37206101 | CMR left ventricular strains beyond global longitudinal strain in differentiating light-chain cardiac amyloidosis from hypertrophic cardiomyopathy. | Front Cardiovasc Med | 2023 | https://conductscience.org/library/papers/37206101 | PubMed |
| 37185672 | Systemic AL amyloidosis: current approach and future direction. | Oncotarget | 2023 | https://conductscience.org/library/papers/37185672 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20194151
GET https://conductscience.org/api/papers/v1/20194151/references?page=2